A Phase 2 interventional study of KH001 and Placebo in Dentin Hypersensitivity, sponsored by HysensBio Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by HysensBio Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity.
This study is multicenter, double-blind, placebo-controlled, randomized, parallel-designed, phase 2 study to evaluate the efficacy and safety of KH001. The total duration of the study will be approximately 7 to 11 weeks. Clinical safety evaluations will include physical examinations, vital signs, clinical laboratory results, and Adverse Event monitoring.
290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.
This study's enrollment of 171 is above the median of 60 across 280 interventional studies indexed under Dentin Sensitivity.
Browse Dentin Sensitivity studies →HysensBio Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KH001 0.2mg/mL
Drug: KH001
KH001 0.4mg/mL
Drug: KH001
Water for Injection
Drug: Placebo
topical applications of KH001
topical applications of Water for Injection
Change from baseline in Schiff sensitivity score
Schiff sensitivity score 0-3 by air blast
Time frame: Baseline and Day 36
Change from baseline in a Schiff sensitivity score
Schiff sensitivity score 0-3 by an evaporative air
Time frame: Baseline, Day 8, 15, 22 and 43
Change from baseline in a Tactile threshold
Tactile threshold by yeaple probe
Time frame: Baseline, Day 8, 15, 22, 36 and 43
Change from baseline in Visual Analogue Scale
100mm Visual Analogue Scale
Time frame: Baseline, Day 8, 15, 22, 36 and 43
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Sep 2024, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KH001